Jw Pharmac (001060) - Total Assets
Based on the latest financial reports, Jw Pharmac (001060) holds total assets worth ₩621.61 Billion KRW (≈ $421.25 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jw Pharmac - Total Assets Trend (2000–2025)
This chart illustrates how Jw Pharmac's total assets have evolved over time, based on quarterly financial data. Also see Jw Pharmac market capitalisation for the company's overall valuation and market capitalisation.
Jw Pharmac - Asset Composition Analysis
Current Asset Composition (December 2025)
Jw Pharmac's total assets of ₩621.61 Billion consist of 49.0% current assets and 51.0% non-current assets. Review 001060 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.5% |
| Accounts Receivable | ₩114.57 Billion | 18.9% |
| Inventory | ₩109.90 Billion | 18.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩64.46 Billion | 10.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Jw Pharmac's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Jw Pharmac share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jw Pharmac's current assets represent 49.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2025, down from 15.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 18.9% of total assets.
Jw Pharmac Competitors by Total Assets
Key competitors of Jw Pharmac based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Jw Pharmac - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.46 | 1.48 | 1.39 |
| Quick Ratio | 0.92 | 0.92 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩97.54 Billion | ₩104.34 Billion | ₩95.65 Billion |
Jw Pharmac - Advanced Valuation Insights
This section examines the relationship between Jw Pharmac's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.60 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | ₩605.27 Billion |
| Market Capitalization | $426.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jw Pharmac's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jw Pharmac's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jw Pharmac (2000–2025)
The table below shows the annual total assets of Jw Pharmac from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩605.27 Billion ≈ $410.18 Million |
+0.11% |
| 2024-12-31 | ₩604.60 Billion ≈ $409.73 Million |
-6.27% |
| 2023-12-31 | ₩645.04 Billion ≈ $437.13 Million |
+2.72% |
| 2022-12-31 | ₩627.97 Billion ≈ $425.57 Million |
-0.80% |
| 2021-12-31 | ₩633.05 Billion ≈ $429.01 Million |
+15.29% |
| 2020-12-31 | ₩549.09 Billion ≈ $372.11 Million |
-4.21% |
| 2019-12-31 | ₩573.21 Billion ≈ $388.45 Million |
-3.47% |
| 2018-12-31 | ₩593.79 Billion ≈ $402.40 Million |
-5.88% |
| 2017-12-31 | ₩630.87 Billion ≈ $427.53 Million |
-3.10% |
| 2016-12-31 | ₩651.08 Billion ≈ $441.23 Million |
+6.13% |
| 2015-12-31 | ₩613.48 Billion ≈ $415.75 Million |
+3.26% |
| 2014-12-31 | ₩594.12 Billion ≈ $402.63 Million |
+0.81% |
| 2013-12-31 | ₩589.37 Billion ≈ $399.41 Million |
-2.28% |
| 2012-12-31 | ₩603.15 Billion ≈ $408.74 Million |
-9.59% |
| 2011-12-31 | ₩667.09 Billion ≈ $452.08 Million |
+29.32% |
| 2006-12-31 | ₩515.85 Billion ≈ $349.58 Million |
+7.92% |
| 2005-12-31 | ₩477.97 Billion ≈ $323.91 Million |
+4.46% |
| 2004-12-31 | ₩457.56 Billion ≈ $310.08 Million |
+11.06% |
| 2003-12-31 | ₩412.00 Billion ≈ $279.21 Million |
+6.85% |
| 2002-12-31 | ₩385.60 Billion ≈ $261.32 Million |
+0.08% |
| 2001-12-31 | ₩385.28 Billion ≈ $261.10 Million |
-3.06% |
| 2000-12-31 | ₩397.46 Billion ≈ $269.35 Million |
-- |
About Jw Pharmac
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more